Fresenius Medical Care AG & Co. KGaA
- WKN: 578580
- ISIN: DE0005785802
- Land: Deutschland
Nachricht vom 17.09.2012 | 08:17
Fresenius Medical Care AG & Co. KGaA: Announces Management Board Change
|
Fresenius Medical Care AG & Co. KGaA / Key word(s): Change of Personnel September 17, 2012 Fresenius Medical Care Announces Management Board Change Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA ('the company' or 'Fresenius Medical Care'), the world's largest provider of dialysis products and services, today announced a change in its Management Board. The Supervisory Board of Fresenius Medical Care Management AG has appointed Ronald (Ron) Kuerbitz as a Management Board member, effective January 1, 2013. Mr. Kuerbitz will succeed Rice Powell as CEO of Fresenius Medical Care North America. This appointment is part of the company's succession plan to ensure a smooth transition of leadership in North America. Mr. Powell will assume the role of CEO, Fresenius Medical Care AG & Co. KGaA, and Chairman of the Management Board, effective January 1, 2013 as announced in March of 2012. Ron Kuerbitz currently serves as Executive Vice President responsible for Market Development and Administration for Fresenius Medical Care North America. He joined Fresenius Medical Care in 1997 to lead its corporate development function and was later named as Fresenius Medical Care North America's General Counsel and Chief Administrative Officer. Mr. Kuerbitz has 20 years of experience in the health care field, having held positions in law, compliance, business development, government affairs and operations. Since 2011 Mr. Kuerbitz has served as Chairman of Kidney Care Partners in Washington D.C., a coalition of patient advocates, dialysis professionals, care providers and device and pharmaceutical manufacturers working together to improve the quality of care for individuals with chronic kidney disease. Mr. Kuerbitz is a graduate of Albion College and received his juris doctor degree from the Yale Law School. 'We are pleased to facilitate an orderly transition process with the appointment of Ron Kuerbitz as CEO for Fresenius Medical Care North America,' said Ben Lipps, Chief Executive Officer of Fresenius Medical Care and Chairman of the Management Board. 'Ron's successful record and his extensive management experience within Fresenius Medical Care and the health care field qualify him superbly for the position. The fact that this appointment has been filled internally reflects the strength and depth of our management team and will ensure a smooth transition going forward'. Ulf Mark Schneider, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said: 'Ron has made outstanding contributions to the success of Fresenius Medical Care over the years. With his superb understanding of the strategic and regulatory opportunities and challenges ahead of us, Ron's leadership will ensure the continued success of the company. We are looking forward to working with him in his new role'.
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more For more information about Fresenius Medical Care, visit the Company's website at www.fmc-ag.com.
Disclaimer End of Corporate News 17.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Fresenius Medical Care AG & Co. KGaA | |
| Else-Kröner-Straße 1 | ||
| 61352 Bad Homburg | ||
| Germany | ||
| Phone: | +49 (0) 6172- 609 2525 | |
| Fax: | +49 (0) 6172- 609 2301 | |
| E-mail: | ir@fmc-ag.com | |
| Internet: | www.fmc-ag.de | |
| ISIN: | DE0005785802, DE0005785836, | |
| WKN: | 578580, 578583 | |
| Indices: | DAX | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart; Terminbörse EUREX; NYSE | |
| End of News | DGAP News-Service |
| 185342 17.09.2012 |
Interaktiv
Weitere News
-
17.05.13 17:35
Fresenius Medical Care AG & Co. KGaA: Announce ... -
30.04.13 20:54
Fresenius Medical Care AG & Co. KGaA: Release ... -
30.04.13 17:08
Fresenius Medical Care AG & Co. KGaA: Release ... -
04.04.13 07:34
Fresenius Medical Care AG & Co. KGaA: Freseniu ... -
04.04.13 07:02
Fresenius Medical Care AG & Co. KGaA: Freseniu ...
Anleihe im Fokus
7,75% p.a. - Rendite aus Familienhand
– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs
GBC-Fokusbox
Syzygy AG: Aktie kaufen
Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.
Event im Fokus
38. m:access Analystenkonferenz München
Datum: 06.06.2013
Zeit: 9:30 Uhr - 17.00 Uhr
Ort: Börse München
Der AKTIONÄR News

25. Mai 16:45 Maximieren Sie Ihren Ertrag in nur 30 Minuten! (Freenet +370% / ...
25. Mai 10:00 3D Systems: Merken Sie sich dieses Datum
25. Mai 09:30 Commerzbank oder Deutsche Bank: Welche Aktie ist billiger?
25. Mai 09:00 DAX-Check: Nikkei verdirbt die Laune
25. Mai 09:00 VW-Aktie: Kursziel 200 Euro
Aktuelle Research-Studie
Original-Research: getgoods.de Anleihe (von GBC AG): stark überdurchschnittlich attraktiv getgoods.de Anleihe
24. Mai 2013